Xtl Biopharmaceuticals (XTLB) Liabilities and Shareholders Equity (2009 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $166000.0 the latest figure, recorded in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 98.06% year-over-year to $166000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18.7 million (down 19.2% YoY) and the FY2025 annual result came in at $166000.0, down 98.06% from the prior year.
• Liabilities and Shareholders Equity eased to $166000.0 in Q4 2025 per XTLB's latest filing, from $714000.0 in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for XTLB reached as high as $9.3 million in Q3 2024 and fell as low as $166000.0 in Q4 2025.
• A 5-year average of $4.7 million and a median of $4.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 252.43% — and 2025, when it slumped 98.06%.
• Year by year, Liabilities and Shareholders Equity stood at $6.6 million in 2021, then tumbled by 36.75% to $4.2 million in 2022, then sank by 42.04% to $2.4 million in 2023, then jumped by 252.43% to $8.5 million in 2024, then sank by 98.06% to $166000.0 in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $166000.0, $714000.0, and $8.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.